1243P Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis
Nathalie Waser, Ahmed Adam, Bernd Schweikert, L. Vo, M. McKenna, Mary Alice B. Breckenridge, J.R. Penrod, Sarah Goring
Topics & Concepts
MedicineInternal medicineHazard ratioMeta-analysisClinical endpointOncologySubgroup analysisLung cancerNeoadjuvant therapyRandomized controlled trialSample size determinationPopulationPathologicalRandom effects modelRadiation therapySurrogate endpointProportional hazards modelCancerConfidence intervalBreast cancerMathematicsEnvironmental healthStatisticsLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical ImagingLung Cancer Treatments and Mutations